YHLO's National-level Key Project Officially Launched
On December 16th, YHLO in collaboration with Professor Zhou Zhou from Fuwai Hospital of the Chinese Academy of Medical Sciences, has taken the lead in the initiation of the "R&D of High-performance Immune On-site Rapid Diagnosis System" project. Aligned with the "Diagnostic Devices and Biomedical Materials" key task of the Chinese National Key R&D Program, this project aims to propel the high-quality development of cardiovascular disease diagnosis and treatment. Experts discussed the cutting-edge progress in the diagnosis and treatment of cardiovascular diseases.
Cardiovascular disease is the disease with the highest fatality rate among Chinese residents, placing a serious burden on society and families. Its acute and severe disease onset is rapid, progresses quickly, and the condition is severe. It requires the cooperation of multiple departments to carry out rapid and standardized diagnosis and treatment of patients. Otherwise, the patient's prognosis will be seriously affected. Based on this, there is an urgent clinical need for more accurate and faster on-site immune detection technology to seize the golden rescue period and achieve the purpose of reducing the death and disability rate of the disease.
The "R&D of High-performance Immune On-site Rapid Diagnosis System" project is an important part of the key special task of "Diagnostic and Treatment Equipment and Biomedical Materials" of the Chinese National Key R&D Plan. It will focus on the on-site rapid diagnosis device for cardiovascular and cerebrovascular emergencies, research and development of core components. High-performance in vitro diagnostic devices can comprehensively improve existing medical service capabilities in specific scenarios such as critical illness.
After the project launch ceremony, many authoritative experts and industry elites in the cardiovascular field participated in the academic conference to exchange cutting-edge advances in the diagnosis and treatment of cardiovascular diseases.
This project is based on on-site rapid immune detection technology and highly integrated sample preprocessing and detection processes based on microfluidic chips, which can accurately, quickly and conveniently diagnose cardiovascular and cerebrovascular diseases, and solve the pain points of cardiovascular disease diagnosis and treatment.